Department of Technology and Product Development, CK Life Sciences Int'l., (Holdings) Inc., 2 Dai Fu Street, Tai Po Industrial Estate, Hong Kong SAR, China.
Cancer Lett. 2010 Aug 1;294(1):118-24. doi: 10.1016/j.canlet.2010.01.029. Epub 2010 Feb 11.
Cucurbitacin B is an anti-cancer drug candidate and its efficacy has been demonstrated in hepatocellular carcinoma (HCC). To explore its mechanism against HCC, BEL-7402 cells were treated with cucurbitacin B in vitro. Treatment with cucurbitacin B induced S phase arrest and apoptosis. The growth inhibition effect was associated with cyclin D1 and cdc-2 down regulations. Western blotting analysis of cell signaling molecules indicated that cucurbitacin B inhibited c-Raf activation without affecting STAT3 phosphorylation. Moreover, in vivo study demonstrated that cucurbitacin B is effective against BEL-7402 xenograft when administrated orally.
葫芦素 B 是一种抗癌候选药物，其在肝细胞癌（HCC）中的疗效已得到证实。为了探索其对 HCC 的作用机制，将 BEL-7402 细胞用葫芦素 B 进行体外处理。葫芦素 B 处理诱导 S 期阻滞和细胞凋亡。生长抑制作用与细胞周期蛋白 D1 和 cdc-2 的下调有关。细胞信号分子的 Western blot 分析表明，葫芦素 B 抑制 c-Raf 的激活而不影响 STAT3 的磷酸化。此外，体内研究表明，葫芦素 B 口服给药对 BEL-7402 异种移植物有效。
